MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	10/8/2007 8:36:43 AM
	of 1826

Merrill on MOGN: MGI Pharma (MOGN, US$29.75, C-1-9) Raising PO to $35 on greater Aloxi confidence We raised our PO to $35, based primarily on greater confidence in Aloxi’s sales. We increased our 3Q07 Aloxi projection to $65 MM, which is now above consensus of $61 MM, and also our ’07 EPS est. Aloxi’s strength is due to favorable profitability for oncologists, active promotion, and a solid clinical profile. In addition, we added Aquavan and AKR-501 to our valuation. We estimate Aloxi is worth $20.50 based on a peak sales estimate of $400 M.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next